Charles River Laboratories InteNYSE: CRL
Health Care · Life Sciences Tools & Services
$165.82
-0.69%
Vol: 399K
Research Digest
Friday, May 1, 2026
Charles River to divest CDMO and Cell Solutions to GI Partners; Q1 earnings due May 7
Charles River will release Q1 2026 results on May 7 before market open (consensus EPS $1.96, down 16.2% YoY). Company signed definitive agreements to sell CDMO and Cell Solutions businesses to GI Partners (contingent payments) and European Discovery Services assets to IQVIA for ~$145M. Faces declining organic revenue and reduced 2026 outlook. Analyst consensus Buy with $198.27 PT.
Previous Market Intelligence
13 daysApr 30Charles River announces Q1 earnings scheduled for May 7 amid reduced 2026 outlookMixed▶
Charles River Laboratories faces mixed sentiments with a 16.2% projected EPS decline year-over-year. The company signed agreements to divest European Discovery Services assets and CDMO/Cell Solutions businesses to GI Partners and IQVIA. Q1 2026 earnings release scheduled for May 7 before market open. Recent strategic moves include acquiring PathoQuest SAS for NGS solutions and K.F. (Cambodia) Ltd for non-human primate supply.
Apr 16Charles River announced divestitures of CDMO and European Discovery units on April 1; RBC upgraded April 15Mixed▶
Charles River Laboratories announced major restructuring on April 1, 2026 including divestiture of CDMO and Cell Solutions units plus European Discovery Services assets. Divestitures will reduce 2026 revenue by $200M+, with 50bps+ margin improvement. CEO James Foster retired, with COO Birgit Girshick succeeding him. New CFO Glenn Coleman started April 6. Royal Bank of Canada upgraded the stock to moderate buy on April 15. JPMorgan lowered price target to $160 from $165 on April 13. Stock closed April 9 at $175.55.
Apr 15Charles River Labs announced strategic divestitures, new CEO and CFO appointments, and accelerated cost restructuring.Mixed▶
Charles River announced James C. Foster will retire as CEO on May 5, 2026, with COO Birgit Girshick appointed as successor. The company divested underperforming units representing ~7% of 2025 revenue, projecting at least $0.30 annual EPS accretion plus $225M annualized restructuring savings. CRL signed an MOU with NSG Bio on April 9 for Asia biomanufacturing partnerships. The stock rebounded to $175.55 by April 9 (up 75.99% over 52 weeks).
Apr 14Charles River Laboratories divests CDMO and EU discovery units to boost margins; signs Asia partnership.Mixed▶
Charles River announced significant divestitures: selling CDMO and Cell Solutions to GI Partners and divesting EU discovery assets to IQVIA for $145M. Signed MOU with NSG Bio for Singapore infrastructure. New CFO started April 6. EPS guidance raised to $10.70-$11.20. Stock closed at $175.55 with 52-week gains of 76%.
Apr 13Charles River Laboratories faces stock decline after divestiture plans and leadership transition announced.Mixed▶
Charles River announced plans to divest CDMO and Cell Solutions businesses plus European Discovery Services, causing 4% stock drop. New CFO started April 6; CEO retiring at 2026 Annual Meeting. Stock positioned to benefit from biotech funding recovery. Median analyst target is $199.
Apr 10Charles River Laboratories announced divestitures of CDMO and European assets; CEO James Foster retiring May 5.Mixed▶
Charles River Laboratories is divesting CDMO, Cell Solutions, and European Discovery Services assets to IQVIA and GI Partners, expected to reduce revenue by $200M+ while improving margins by 100bps+. CEO James Foster retires May 5 with COO Birgit Girshick succeeding him. Company lowered 2026 adjusted EPS guidance to $10.70-$11.20. Stock down 4.0% on April 6. Consensus Moderate Buy with $202.36 target (28.1% upside).
Apr 9Charles River Laboratories divests CDMO and European assets for future performance paymentsNeutral▶
Charles River signed definitive agreements to divest CDMO and Cell Solutions businesses to GI Partners for primarily contingent performance-based payments. Also selling certain European Discovery Services assets to IQVIA for approximately $145 million cash. Divestitures reduce 2026 revenue by over $200 million but expected to improve non-GAAP operating margin by at least 100 basis points. Q2 2026 closing expected.
Apr 8Charles River Laboratories signs divestitures of CDMO and European assets; revenue expected to decline $200M+ in 2026Negative▶
Charles River Laboratories signed definitive agreements to divest CDMO/Cell Solutions to GI Partners and European Discovery Services assets to IQVIA for ~$145M cash (potential +$10M contingent). Planned divestitures expected to reduce 2026 revenue by slightly over $200M. Stock pressured by divestiture reprice and leadership transition.
Apr 7No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Apr 6Charles River divests CDMO/Cell Solutions to GI Partners and European assets to IQVIA for $145M.Positive▶
Charles River signed agreements to divest CDMO and Cell Solutions to GI Partners and European Discovery Services assets to IQVIA for ~$145M cash. Closes Q2 2026. Reduce revenue ~$200M, improve margins 100+ bps, add ~$0.10 to 2026 EPS. Avg Buy PT $200.09.
Apr 3Charles River plans divestitures: selling CDMO and European Discovery assets; CEO transition May 5.Neutral▶
Charles River announced CEO James Foster will retire May 5 with COO Birgit Girshick as successor. Definitive agreements signed to sell CDMO and Cell Solutions businesses to GI Partners and European Discovery Services assets. Divestitures expected to reduce revenue $200M+ but improve margins 50+ bps.
Apr 2CEO James Foster retiring May 5; Birgit Girshick becomes CEO; company divests CDMO and Cell Solutions units boosting margins.Mixed▶
Charles River announced CEO transition with Birgit Girshick, current EVP/COO, becoming CEO May 5, 2026. Company divests European Discovery Services and CDMO/Cell Solutions businesses expected to reduce revenue by $200M+ in 2026 but add 100 bps operating margin improvement and $0.10 to EPS. Q4 adjusted EPS of $2.39 beat consensus of $2.33. 2026 guidance $10.70-$11.20 EPS. Stock down 20.8% YTD but analysts see 28.1% upside at $202.36 target.
Apr 1Charles River Laboratories plans major divestitures; CEO James Foster to retire May 2026.Mixed▶
Charles River announced definitive agreements to sell CDMO and European Discovery Services assets. Divestitures expected to reduce revenue by $200M+ and improve non-GAAP margin by 100bps+. CEO James Foster to retire May 5; COO Birgit Girshick to succeed.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| CRLCHARLES | $165.82 | -0.69% | -0.7% | 13.5x | 1.62 | $8.2B |
| TMOTHERMO | $469.56 | -1.96% | -1.9% | 17.5x | 0.97 | $178.0B |
| DHRDANAHER | $175.47 | -1.95% | -6.9% | 19.7x | 0.99 | $126.7B |
| AAGILENT | $114.69 | -0.74% | +0.6% | 17.6x | 1.30 | $32.7B |
| WATWATERS | $306.56 | -0.86% | +1.7% | 18.9x | 1.20 | $30.4B |
| IQVIQVIA | $157.04 | -0.84% | -7.2% | 11.3x | 1.39 | $26.6B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price below 200d MA — bearish structure.